Nivolumab plus Ipilimumab in Advanced Melanoma

Nivolumab plus Ipilimumab in Advanced Melanoma

Author: 
Wolchock, J.D. [etal]
Publisher: 
New England Journal of Medicine
Date published: 
2013
Record type: 
Journal Title: 
The New England Journal of Medicine
Source: 
The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 122-133
Abstract: 

A combination of antibodies to two T-cell checkpoints, CTLA-4 and PD-1, produced tumor responses in 40% of patients in a phase 1 study. Elevated lipase levels indicated dose-limiting toxicity.

Language: 

CITATION: Wolchock, J.D. [etal]. Nivolumab plus Ipilimumab in Advanced Melanoma . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 122-133 - Available at: https://library.au.int/nivolumab-plus-ipilimumab-advanced-melanoma-4